The estimated Net Worth of David A Socks is at least $41.1 Million dollars as of 7 October 2021. Mr. Socks owns over 18,000 units of Phathom Pharmaceuticals Inc stock worth over $22,652,170 and over the last 4 years he sold PHAT stock worth over $17,876,955. In addition, he makes $542,127 as Co-Founder, Chief Financial Officer, Treasurer, and Director at Phathom Pharmaceuticals Inc.
David has made over 11 trades of the Phathom Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 18,000 units of PHAT stock worth $586,440 on 7 October 2021.
The largest trade he's ever made was selling 79,658 units of Phathom Pharmaceuticals Inc stock on 16 December 2020 worth over $3,458,750. On average, David trades about 29,933 units every 22 days since 2020. As of 7 October 2021 he still owns at least 1,211,346 units of Phathom Pharmaceuticals Inc stock.
You can see the complete history of Mr. Socks stock trades at the bottom of the page.
David Socks serves as Co-Founder, Chief Financial Officer, Treasurer, Director of the Company. David Socks is our co-founder and has served as our interim Chief Financial Officer and Treasurer since December 2019, and as a member of our board of directors since January 2018. Mr. Socks previously served as our Chief Executive Officer from January 2018 until his appointment as interim Chief Financial Officer in December 2019. Since August 2014, Mr. Socks has been a Venture Partner at Frazier. In this capacity, he co-founded Arcutis, Inc., Nexcida Therapeutics, Inc., Outpost Medicine, LLC, Passage Bio, Inc., Recida Therapeutics, Inc., and Scout Bio, Inc. Mr. Socks served as Chief Executive Officer of Nexcida Therapeutics, Outpost Medicine and Scout Bio. Mr. Socks also serves as a board member of Outpost Medicine. Prior to joining Frazier, Mr. Socks co-founded Incline Therapeutics, Inc. in 2010 and served as its President and Chief Operating Officer from 2010 until its sale to The Medicines Company in 2013. He also cofounded Cadence Pharmaceuticals, Inc. in 2004 and served as its Vice President of Business Development and then as its Senior Vice President, Corporate Development and Strategy from 2004 until 2010. From 2000 to 2004, Mr. Socks was a Venture Partner at Windamere Venture Partners, a venture capital firm founding and investing in early stage life science companies, where he cofounded several biopharmaceutical companies including Somaxon Pharmaceuticals, Inc. and Verus Pharmaceuticals, Inc. Previously, he worked at Neurocrine Biosciences, EFO Holdings, L.P., an investment firm, and Kaiser Associates, Inc., a strategic management consulting firm. Mr. Socks holds a B.S. from Georgetown University and an MBA from Stanford University. Mr. Socks’ knowledge of our business and significant experience as a biopharmaceutical executive and board member, contributed to our board of directors’ conclusion that he should serve as a director of our company.
As the Co-Founder, Chief Financial Officer, Treasurer, and Director of Phathom Pharmaceuticals Inc, the total compensation of David Socks at Phathom Pharmaceuticals Inc is $542,127. There are 3 executives at Phathom Pharmaceuticals Inc getting paid more, with Terrie Curran having the highest compensation of $3,459,100.
David Socks is 45, he's been the Co-Founder, Chief Financial Officer, Treasurer, and Director of Phathom Pharmaceuticals Inc since 2019. There are 12 older and 2 younger executives at Phathom Pharmaceuticals Inc. The oldest executive at Phathom Pharmaceuticals Inc is Tadataka Yamada, 75, who is the Independent Chairman of the Board.
David's mailing address filed with the SEC is C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PAK, NJ, 07932.
Over the last 5 years, insiders at Phathom Pharmaceuticals Inc have traded over $112,538,769 worth of Phathom Pharmaceuticals Inc stock and bought 2,393,679 units worth $45,337,731 . The most active insiders traders include Capital Management, L.P.Ra ..., James N Topper, and Pharmaceutical Co Ltd Takeda. On average, Phathom Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $2,226,815. The most recent stock trade was executed by Azmi Nabulsi on 15 July 2024, trading 10,901 units of PHAT stock currently worth $127,760.
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
Phathom Pharmaceuticals Inc executives and other stock owners filed with the SEC include: